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Abstract
Background: In diagnosing celiac disease (CD), serological tests are highly valuable. However, their role in
following up children with CD after prescription of a gluten-free diet is unclear. This study aimed to compare the
performance of antibody tests in predicting small-intestinal mucosal status in diagnosis vs. follow-up of pediatric CD.
Methods: We conducted a prospective cohort study at a tertiary-care center. 148 children underwent
esophohagogastroduodenoscopy with biopsies either for symptoms ± positive CD antibodies (group A; n = 95) or
following up CD diagnosed≥ 1 year before study enrollment (group B; n = 53). Using biopsy (Marsh≥ 2) as the
criterion standard, areas under ROC curves (AUCs) and likelihood-ratios were calculated to estimate the performance
of antibody tests against tissue transglutaminase (TG2), deamidated gliadin peptide (DGP) and endomysium (EMA).
Results: AUCs were higher when tests were used for CD diagnosis vs. follow-up: 1 vs. 0.86 (P = 0.100) for TG2-IgA, 0.85
vs. 0.74 (P = 0.421) for TG2-IgG, 0.97 vs. 0.61 (P = 0.004) for DPG-IgA, and 0.99 vs. 0.88 (P = 0.053) for DPG-IgG, respectively.
Empirical power was 85% for the DPG-IgA comparison, and on average 33% (range 13–43) for the non-significant
comparisons. Among group B children, 88.7% showed mucosal healing (median 2.2 years after primary diagnosis). Only
the negative likelihood-ratio of EMA was low enough (0.097) to effectively rule out persistent mucosal injury. However,
out of 12 EMA-positive children with mucosal healing, 9 subsequently turned EMA-negative.
Conclusions: Among the CD antibodies examined, negative EMA most reliably predict mucosal healing. In general,
however, antibody tests, especially DPG-IgA, are of limited value in predicting the mucosal status in the early years
post-diagnosis but may be sufficient after a longer period of time.
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Background
Celiac disease (CD) is a multi-systemic autoimmune dis-
ease triggered by exposure to dietary gluten in genetically
predisposed individuals. CD creates small-intestinal muco-
sal injury of different severity [1]. An effective treatment
allowing mucosal healing is the gluten-free diet (GFD).
The goals of treatment are not only symptomatic improve-
ment but also avoiding complications, which could arise
even in patients having become asymptomatic on a
GFD [2,3]. Furthermore, achieving mucosal healing
might be crucial because of an increased risk of lympho-
proliferative malignancy among patients with persistent
villous atrophy [4].
International CD guidelines propose regular follow-up
of CD patients [5-7]. Among the follow-up modalities, re-
biopsy may be undertaken to prove mucosal healing,
which children achieve more often than adults [8]. How-
ever, its invasiveness, discomfort and possible complica-
tions limit the use of re-biopsy in routine follow-up [5,6].
Therefore, reliable non-invasive surrogate markers of mu-
cosal healing are highly desirable. Whereas antibody tests
* Correspondence: andreas.vecsei@stanna.at
†Equal contributors
1Department of Pediatrics, Pediatric Gastroenterology, St. Anna Children's
Hospital, Medical University Vienna, Kinderspitalgasse 6, 1090 Vienna, Austria
Full list of author information is available at the end of the article
© 2014 Vécsei et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Vécsei et al. BMC Gastroenterology 2014, 14:28
http://www.biomedcentral.com/1471-230X/14/28
are of irreplaceable value in diagnosing untreated CD [6],
controversy exists over whether these tests can reliably in-
dicate mucosal healing [8-11].
Concerning the correlation between follow-up histology
and non-invasive biomarkers, children with CD are an
understudied population. Specifically, there is a lack of pro-
spective pediatric studies evaluating current biomarkers
used in clinical practice for monitoring purposes.
The purpose of this study was to prospectively com-
pare the performance of up-to-date antibody tests in
predicting mucosal status in children with untreated CD
vs. in children after prescription of a GFD.
Methods
Study design and subjects
Between July 1, 2009, and December 31, 2010, a prospect-
ive, cross-sectional cohort study was performed at St.
Anna Children’s Hospital. Following written informed par-
ental consent, all consecutively enrolled children (n = 148)
underwent esophagogastroduodenoscopy with biopsies
(EGD). The participating children were divided into
groups according to whether EGD was performed for
diagnostic or follow-up purposes (Figure 1).
Group A comprised 95 children on a gluten-containing
diet, 32 of them became diagnosed with CD (group A1)
and 63 were referred to EGD due to non-celiac dyspepsia
(group A2). The predominant complaints in group A1 chil-
dren were abdominal pain (31.3%), failure to thrive or short
stature (18.8%), chronic diarrhea (6.3%), flatulence (6.3%),
recurrent headache (6.3%) and constipation (3.1%). A first-
degree relative with CD (18.8%), IgA-deficiency (3.1%),
autoimmune thyroiditis (3.1%), and iron deficiency anemia
(3.1%) were the remaining reasons for CD screening in
group A1. Diagnosis of CD was based on positive IgA anti-
bodies against endomysium (EMA) in IgA-competent chil-
dren or IgG-antibodies against deamidated gliadin peptides
(DGP-IgG) in children with IgA-deficiency along with bi-
opsy results consistent with CD (Marsh ≥ 2) and positivity
of HLA-DQ2 and/or HLA-DQ8. CD was ruled out by
negative biopsy results.
1206 children 
presenting to a single pediatric gastroenterology outpatient clinic
from July 2009 until December 2010
174 eligible children presenting 
•either with serologically suspected untreated CD, n=32
•or with dyspepsia for esophagogastroduodenoscopy with biopsies, n=63 
•or for re-biopsy of CD,    1 year after prescription of a GFD, n=79
26 children presenting for 
CD follow-up refused to 
undergo re-biopsy
Group A1 
(CD before prescription 
of a GFD)
n=32
Group A2 
(non-celiac dyspepsia)
n=63
Group B 
(CD after prescription of a GFD)
n=53
148 children enrolled
1032 non-eligible children
Group A 
n=95
Figure 1 Recruitment flow chart.
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Group B comprised 53 children with CD after pre-
scription of a GFD ≥ 1 year before study enrollment (me-
dian 2.2, range 1 to 12.9). CD had been proven by
positive EMA or IgA antibodies against tissue transglu-
taminase (TG2-IgA), biopsy evidence and positivity of
HLA-DQ2 and/or HLA-DQ8. Group B children had re-
ceived regular follow-up according to the recommenda-
tions then in force [7]. Within the 18-month study
period, a total of 79 children presented for routine CD
follow-up. All of these children were invited to partici-
pate in the study independent of the presence of symp-
toms or their adherence to the GFD according to dietary
interview. As such they were unselected and only chosen
by their willingness to undergo follow-up endoscopy. In
this context, 26 of 79 eligible children opted out of the
study. The predominant complaints in group B were ab-
dominal pain (15.1%), constipation (1.9%) and aphthous
stomatitis (1.9%). Within group B, 79.2% of children
were symptom-free.
Endoscopy, biopsies and histology
All EGDs were performed in anesthesiologist-controlled
deep sedation with propofol. Four biopsies were taken
from the second part and two from the bulb of the duo-
denum. Biopsies were staged by two experienced pathol-
ogists (GA and AC) who were blinded to subject identity
and indication for biopsy. Intestinal histological findings
were classified according to a modified Marsh classifica-
tion [1] using ≥ 30 lymphocytes/100 epithelial cells as
cut-off for pathological intraepithelial lymphocytosis
[12]. In cases of initial disagreement, a consensus diag-
nosis was reached using a multihead microscope. Muco-
sal healing in group A was defined as Marsh < 2.
CD serology
Blood for serology was taken in the week before EGD. In
all children, total IgA levels were determined. IgA-
deficiency was defined as serum IgA < 0.07 g/L [13]. All
IgA-based tests were evaluated only after exclusion of
IgA-deficient children. Four commercial enzyme-linked
immunosorbent assays were used for detection of TG2-
IgA, TG2-IgG, DPG-IgG, and DPG-IgA (Table 1). Sera
were also tested for EMA by indirect immunofluores-
cence using monkey esophagus (Table 1), at the initial
dilution of 1:5 and, when positive, titrated up to the end
point. A single experienced technician assessed all slides.
CD serology kits from different companies were used be-
cause Eurospital TG2-IgA and Orgentec EMA had been
our routine test kits since 2005 onwards and on request
Werfen Austria, Diagnostic Divisions, was willing to
complete the armamentarium of current CD antibodies
by providing Inova antibody kits free of charge during
the study.
Statistics
Data of continuous and categorical variables were reported
using median and interquartile range (IQR) on the one
hand and counts and percentages on the other hand. For
comparisons on categorical data chi-square and Fisher
exact test were used while Mann–Whitney U and Kruskal-
Wallis tests were used to compare continuous data. Unless
otherwise specified, Bonferroni correction was applied for
multiple comparisons in post-hoc-tests. Kappa coefficients
were used to examine agreement among pathologists in
classifying histological findings. Performances of non-
invasive tests were evaluated by ROC curve analysis. Areas
under ROC curves (AUC), summary measures of overall
diagnostic performance, were reported with their 95%
Table 1 Antibody tests for celiac disease used in the study
Assays Manufacturer’s
cut-off (U/ml)
Optimal ROC cut-off for diagnosing
untreated CD (U/ml)
Optimal ROC cut-off for monitoring
treated CD (U/ml)
Endomysial IgA antibodies assay
ORG 802/ORG 872 Anti-Endomysium
Antibodies kit
1:5 - 1:5
Orgentec Diagnostika GmbH, Mainz, Germany
Anti-tissue transglutaminase assays
Eu-tTG umana IgA, Eurospital, Trieste, Italy 9 16.4 11.9
Quanta Lite h-tTG IgG ELISA, Inova
Diagnostics
20 7.8 10.3
Antibodies against deamidated gliadin peptide
assays
Quanta Lite Gliadin IgA II ELISA, Inova Diagnostics,
San Diego, USA
20 8.0 8.2
Quanta Lite Gliadin IgG II ELISA, Inova Diagnostics,
San Diego, USA
20 11.6 11.9
ROC, receiver operating characteristic; CD, celiac disease; ELISA, enzyme-linked immunosorbent assay.
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confidence intervals (CIs); AUC > 0.9 was considered a
high diagnostic test performance [14]. To rank the per-
formance of tests when used for diagnosing CD, AUCs of
ROC curves derived from group A were compared [15].
To rank the performance of tests when used for follow-up
monitoring of CD, AUCs of ROC curves derived from
group B cases were compared. Furthermore, we compared
the performance of each single test when used for diagno-
sis vs. for follow-up monitoring of CD [16]. We also used
ROC curve analysis to determine the optimal cut-off point
for each test and calculated further performance measures
like sensitivity, specificity, positive and negative likelihood-
ratios (LR + and LR-) with 95% CIs. Where there was a
2x2 table with an empty cell 0.5 was added to each cell.
Tests with either a LR+ > 10 or LR- < 0.1 were considered
informative and clinically useful [17]. Statistical calcula-
tions were performed with SPSS, version 20.0 (SPSS,
Chicago, Ill), and the free software R [18]. For all statistical
analyses, Bonferroni corrected two-tailed P-values < 0.05
were considered significant.
Ethics approval
The Institutional Review Board at St. Anna Children’s
Hospital approved this study. Since obtaining follow-up
biopsies in children with CD deviates from our clinical
practice, all group B children were covered by a clinical
trial insurance policy valid throughout the 18-month
study period.
Results
Demographics
Age of the 148 children ranged from 2 to 19 years (median
11.3). Children with newly diagnosed CD (group A1) were
younger (median age in years [IQR, min to max]: 7.8 [6.2,
2.0 to 17.6]) than both dyspeptic children (group A2)
(median age in years [IQR, min to max]: 12.6 [5.3, 3.3 to
18.0]) and group B children (median age in years [IQR,
min to max]: 11.8 [4.8, 4.2 to 19.1]) (P < 0.001). In all
groups, girls outnumbered boys (girls/boys in group A1:
23/9; in group A2: 48/15; in group B: 33/20) (P = 0.26).
Performance of antibody tests in group A
In predicting mucosal status in group A, TG2-IgA,
DGP-IgA and DGP-IgG assays showed high diagnostic
performance, exhibiting AUCs ≥ 0.96 (Figures 2 and 3,
Table 2). TG2-IgG performed less well, exhibiting an
AUC of about 0.85.
Within group A1, all children had positive EMA, posi-
tive EMA being an inclusion criterion. Therefore, no
performance evaluation for EMA using ROC curve ana-
lysis was done in group A.
Within group A2, positive EMA were found in 3 chil-
dren (specificity 0.94; 95% CI 0.86 to 0.99) who all had
Marsh 0 as the result of the small intestinal biopsy. Of
these EMA-positive group A2 children, 2 tested positive
for TG2-IgA as well. In 2 children, all antibody titres
normalized on follow-up under gluten-containing diet
within 6 months. One these two children still had Marsh 2
in a follow-up biopsy 28 months later. The third EMA-
positive group A2 child was placed on a GFD by her par-
ents for 2.5 years before presenting for follow-up visit. At
this visit, she was seronegative. She is currently undergo-
ing a gluten challenge from November 2012 onwards. At
her last visit in October 2013 she was still seronegative.
Performance of antibody tests in group B
Comparing the performance of antibody tests in predict-
ing mucosal status in group A vs. B, all tests performed
less well in group B (Figures 2 and 3, Table 2). This per-
formance loss was significant at an uncorrected level of
alpha = 0.05 in case of DPG-IgA (Puncorr. = 0.004). Em-
pirical power (calculated using 1000 bootstrap samples)
was 85% for this comparison, and on average 33% (range
13–43) for the non-significant comparisons. Within
group B, EMA performed best followed by DGP-IgG
and TG2-IgA.
Among the LRs obtained in group B, only the negative
LR of EMA was low enough (0.097) to effectively rule
out persistent mucosal injury (Table 2).
However, within group B, positive EMA were detected
in 18 children, 12 of whom exhibited mucosal healing.
Of these children with EMA-positivity despite mucosal
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Figure 2 Areas under ROC curves (AUCs) of antibody tests used in
diagnosing untreated coeliac disease vs. monitoring coeliac
disease after prescription of a gluten-free diet. Significant results are
marked with asterisks. Anti-TG2 IgA and -IgG, anti-tissue transglutaminase
IgA and -IgG; EMA, anti-endomysial antibodies IgA; anti-DGP IgA and
-IgG, anti-deamidated-gliadin-peptide IgA and -IgG.
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healing, all 12 had Marsh 0 as the result of the small intes-
tinal biopsy; 9 (75%) became EMA-negative on further
follow-up within the next 20 months. Before study enroll-
ment, all of these 12 children initially had EMA ≥ 1:160
and Marsh ≥ 3A at diagnosis except one girl with EMA
1:80 and Marsh 2. On enrollment, all these children
still had positive EMA ranging from 1:5 to 1:80 despite
Marsh 0 in the study biopsies after a median of 1.5 years
on a GFD. Comparing the duration of the GFD in group B
children with mucosal healing, EMA-positive children had
been on the GFD for a shorter period of time (median age
in years [IQR, min to max]: 1.5 [0.8, 1.0 to 3.0]) than the
EMA-negative children (median age in years [IQR, min to
max]: 2.3 [5.5, 1.0 to 12.9]) (P = 0.008).
Overall, of the group B children exhibiting Marsh 0, 4
had positive TG2-IgA, 15 positive TG2-IgG, 12 positive
EMA, 16 positive DPG-IgA, and 10 positive DPG-IgG. All
35 EMA-negative group B children with mucosal healing
(34 children with Marsh 0 and one with Marsh 1) also had
negative TG2-IgA.
Histology
In group A1, where all children had histology consistent
with CD, severe mucosal injury (Marsh 3B or 3C) was
found in 28 children (87.5%) while the remaining 4 chil-
dren (12.5%) showed Marsh 3a. In group A2, histology
showed gastritis in 39 children, esophagogastritis in 8,
esophagitis in 1, gastric ulcer in 1 and normal mucosa
in 14.
Mucosal healing was found in 47 of 53 (88.7%) group
B children (Figure 4, Table 3). Of these children with
mucosal healing, 46 showed Marsh 0 (86.8%) and one
Marsh 1 (1.8%). Of those children with mucosal injury,
one showed Marsh 2 (1.8%), two Marsh 3a (3.8%) and 3
(5.7%) Marsh 3b (Figure 4).
Good inter-rater reliability among the pathologists was
found, kappa coefficients were 0.81 and 0.74 for the bi-
opsies from the bulb and from the descending part of
the duodenum, respectively. Before reaching consensus,
histological classification differed in 19 children (12.8%);
however, in only 2 of these children, classification
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Figure 3 ROC curves of the antibody tests examined. In case of anti-TG2 IgA and IgG as well as anti-DGP IgG non-significant differences of
AUC between primary diagnosis (solid black line) and follow-up setting (dashed grey line) were found while in anti-DGP IgA (bottom left)
significant AUC differences were detected. For illustrative purposes, optimal cut-off points (with minimal distance to the upper left corner) are
designated using correspondingly coloured arrows. Circle segments illustrate that the cut-off points chosen are indeed optimal, the diagonal line
in each plot represents the general case of a random guess. Perfect discrimination would result in an ROC curve touching the upper left corner
(100% Sensitivity, 100% Specificity). AUC, area under the curve; anti-TG2, anti-tissue transglutaminase; anti-DGP, antibodies against deamidated
gliadin peptides.
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differences pertained to the presence or absence of mu-
cosal injury (Marsh ≥ 2). The pathologists finally agreed
on Marsh ≥ 2 in both children.
No adverse events of endoscopy including biopsies
were encountered.
IgA-deficient children
In total, four children (2.7%), all girls, were IgA-deficient.
Three girls belonged to group A1, one to group A2.
Discussion
In this study, we provide evidence that antibody tests are
more reliably predicting mucosal status in children with
CD before than in children after prescription of a GFD.
In our patients, according to AUCs (Figure 2), TG2-
IgA, DPG-IgG and DPG-IgA antibody tests performed
very well in diagnosing CD in group A, similar to the
performances reported elsewhere [19]. However, when
used for monitoring mucosal status in CD after a me-
dian of 2.2 years after primary diagnosis (group B), all
tests suffered a performance loss turning out to be sig-
nificant in case of DPG-IgA. According to LRs, add-
itional parameters quantifying the non-invasive tests'
performance, TG2-IgA, DGP-IgG and -IgA antibodies
were most informative and clinically useful with respect
to diagnosing CD in group A. Conversely, the limited
ability to detect mucosal injury in group B was reflected
by LRs + in all tests being < 10. Regarding LRs-, only
negative EMA had an LR- < 0.1 thus being an inform-
ative and clinically useful marker of mucosal healing in
CD [17].
Positive EMA, however, were detected in 18 children
from group B. Twelve of these EMA-positive children
showed mucosal healing, a finding that reflects faster mu-
cosal recovery than EMA-seroconversion. Indeed, EMA-
positive children exhibiting mucosal healing had been on
the GFD for a significantly shorter period of time than the
EMA-negative children. Moreover, 9 of 12 developed
EMA-negativity on further follow-up. This delayed sero-
conversion might partially explain positive EMA in sub-
jects showing mucosal healing [10]. However, adherence
to the dietary treatment was not evaluated in this study
nor was small intestinal mucosa examined for IgA de-
posits [20]. Therefore, we cannot rule out that serum
EMA-positivity is more sensitive than gross histological
damage to detect minor dietary transgressions. Positive
EMA without histological evidence of CD were also de-
tected in 3 children from group A2. EMA normalized on
a normal gluten-containing diet in 2 of the EMA-positive
group B children while the third became seronegative on a
self-prescribed GFD and stayed seronegative even after a
11-month gluten challenge. However, since EMA is a very
Table 2 Performance of antibody tests in diagnosing untreated celiac disease and monitoring treated celiac disease
Primary diagnosis of untreated celiac disease
(Group A, n = 97)
Sens 95% CI Spec 95% CI AUC 95% CI LR+ 95% CI LR- 95% CI
Anti-tissue transglutaminase
Eurospital IgA 1.00 0.85 to 1.00 0.98 0.90 to 1.00 1.00 0.99 to 1.00 41.96 8.62 to 204.13 0.020 0.000 to 0.270
Inova IgG 0.71 0.52 to 0.86 0.86 0.75 to 0.93 0.85 0.77 to 0.93 4.97 2.61 to 9.47 0.340 0.190 to 0.590
Anti-endomysial antibodies
Orgentec IgA 1 0.85 to 1.00 0.85 0.53 to 0.97 - - 5.51 1.79 to 16.95 0.020 0.000 to 0.320
Antibodies against deamidated gliadin peptides
Inova IgA 0.93 0.76 to 0.99 0.94 0.85 to 0.98 0.97 0.94 to 1.00 14.63 5.63 to 37.96 0.080 0.020 to 0.290
Inova IgG 0.97 0.83 to 1.00 0.95 0.87 to 0.99 0.99 0.98 to 1.00 20.32 6.72 to 61.43 0.034 0.000 to 0.230
Monitoring treated celiac disease
(Group B, n = 53)
Anti-tissue transglutaminase
Eurospital IgA 0.83 0.36 to 1.00 0.87 0.74 to 0.95 0.86 0.69 to 1.00 6.53 2.85 to 14.95 0.191 0.032 to 1.147
Inova IgG 0.67 0.22 to 0.96 0.79 0.64 to 0.89 0.74 0.49 to 0.99 3.13 1.42 to 6.90 0.423 0.135 to 1.326
Anti-endomysial antibodies
Orgentec IgA 1.00 0.50 to 1.00 0.74 0.59 to 0.86 0.89 0.80 to 0.98 3.57 2.12 to 5.99 0.097 0.070 to 1.403
Antibodies against deamidated gliadin peptides
Inova IgA 0.67 0.22 to 0.96 0.66 0.51 to 0.79 0.61 0.38 to 0.84 1.96 0.98 to 3.91 0.505 0.160 to 1.596
Inova IgG 0.83 0.36 to 1.00 0.77 0.62 to 0.88 0.88 0.76 to 0.99 3.56 1.90 to 6.68 0.218 0.036 to 1.311
Sens, sensitivity; Spec, specificity; CI, confidence interval; AUC, area under the curve; LR+, positive likelihood-ratio; LR-, negative likelihood-ratio.
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strong predictor of a subsequent CD diagnosis [21], there
is need of further follow-up in these children including
endoscopy.
All the children participating in the study underwent
EGD as criterion standard for the evaluation of the diag-
nostic reliability of the antibody tests. In the light of the
possibility to diagnose CD without biopsies [6], an import-
ant finding of our study was that experiences with the
diagnostic biopsy did not deter two thirds of the children
eligible for group B from undergoing re-biopsy. We found
mucosal healing in the majority of the re-biopsied chil-
dren, 90% of them had Marsh < 2. All group B children
with mucosal injury were ≥ 9 years old and belonged to
the subgroup that had been on a GFD < 2 years. In chil-
dren, the long-term mucosal healing rate was reported to
be 100% and histological recovery might even occur after
more than 2 years after primary diagnosis [22]. In contrast,
it has been shown that children diagnosed after the age of
4 tend to follow the GFD less strictly and therefore are ex-
pected to have a higher prevalence of mucosal injury [23].
Surprisingly, a very low frequency (1.8%) of isolated in-
crease of intraepithelial lymphocyte count (Marsh 1) was
found among group B children. This finding could be re-
lated to the somewhat high cut-off for an increased intrae-
pithelial lymphocyte count used in the study (≥ 30
lymphocytes/100 epithelial cells).
This study has several strengths. In the first place, it
was conducted in children. Concerning the correlation
between follow-up histology and serology, most of the
studies investigating this correlation were conducted in
adults [2,3,8,9,11,24-27]. However, in one pediatric study
on the value of DGP-antibodies in the follow-up of CD,
2,2 yrs(1,0-12,9) after  
prescription of a gluten-
free diet
Marsh 3c (n=17)
Marsh 3b (n=14)
Marsh 3a (n=16)
Marsh 2 (n=6)
Marsh 3b (n=1)
Marsh 0 (n=16)
Marsh 3b (n=1)
Marsh 3a (n=1)
Marsh 2 (n=1)
Marsh 0 (n=11)
Marsh 3b (n=1)
Marsh 0 (n=15)
Marsh 3a (n=1)
Marsh 0 (n=5)
Group B
Results of initial biopsy 
before study enrolment
Group B
Results of re-biopsy within 
the current study
Figure 4 Comparison of histology results of group B at diagnosis (before study enrollment) with the results of re-biopsies taken during
the study.
Table 3 Comparison of group B children with mucosal healing (Marsh < 2) and mucosal injury (Marsh ≥ 2)
Marsh < 2 Marsh ≥ 2 P
(n = 47) (n = 6)
Serology [n (%)]
Negativity of all antibody tests (anti-tissue transglutaminase IgA and -IgG, anti-deamidated-gliadin-peptide
IgA and -IgG, anti-endomysial antibodies IgA)
22 (46.8) 0 0.035
Positivity of at least one antibody test 25 (53.1) 6 (100)
Chief complaint [n (%)]
Asymptomatic 38 (80.9) 4 (66.7) 0.592
Intestinal symptoms 9 (19.1) 1 (16.7) 1.000
Extraintestinal symptoms 0 1 (16.7) 0.113
Weight-for-age z score, mean ± standard deviation −0.66 ± 1.31 −1.04 ± 2.03 0.529
Height-for-age z score, mean ± standard deviation −0.63 ± 1.21 −1.58 ± 1.74 0.094
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only 13 children had both re-endoscopy and follow-up
serology [28]. Another study with children is of limited
value in the aspect that only seroconverted children
were included [29]. Then, in contrast to the current
study, most of the studies reporting on correlations be-
tween follow-up histology and serologies are retrospect-
ive [2,26,28,29]. Another strength of the current study
was the cut-off point being adjusted for the study popu-
lation in case of all antibody tests according to ROC
analysis (Table 1). This adjustment is especially import-
ant in children since manufacturers’ cut-offs are usually
based on data from adults. A further advantage was the
use of AUCs. AUCs as effective single indicators of the
agreement between a test and a reference standard facili-
tate the comparison of the overall performance between
different non-invasive diagnostic tests [15,16]. Addition-
ally, in order to increase the reliability of the reference
standard, two pathologists, before reaching a consensus
diagnosis, independently reviewed all biopsy samples,
which had been taken according to guidelines [7,30,31].
Furthermore, we were able to systematically examine all
recommended serologic tests. In contrast to recent rec-
ommendations for the use of DGP-IgA in monitoring
treated CD [5], we found that DGP-IgA suffered a sig-
nificant performance loss when used for follow-up in
children. We therefore consider DGP-IgA less reliable
for follow-up purposes compared with EMA, TG2-IgA
and DGP-IgG. For the comparisons regarding the per-
formance loss of the serologic tests other than DGP-IgA,
mean empirical power was rather low, a finding we con-
sider an important limitation of this study. Therefore, fu-
ture research is needed to further clarify the correlation
of EMA, TG2-IgA and DGP-IgG with follow-up hist-
ology or identify other reliable non-invasive follow-up
tests in CD.
Conclusion
In conclusion, this study demonstrates the limited value
of serologic testing in the follow-up of pediatric CD with
respect to the mucosal status. Only the normalization of
EMA indicates mucosal healing with acceptable accur-
acy. As long as there is a lack of more reliable tools for
non-invasive follow-up, EMA should be used as follow-
up tool of first choice. However, more reliable non-
invasive follow-up tools would be of great clinical and
research utility with respect to the individualization of
the GFD strictness and upcoming studies evaluating the
efficacy of new CD treatment modalities, respectively.
Abbreviations
CD: Celiac disease; EMA: Endomysial antibodies; TG2: Tissue transglutaminase;
DGP: Deamidated gliadin petide; AUC: Area under the curve; GFD: Gluten-
free diet; EGD: Esophagogastroduodenoscopy; ROC: Receiver operating
characteristic; IQR: Interquartile range; LR-: Negative likelihood-ratio;
LR+: Positive likelihood-ratio; max: Maximum; min: Minimum.
Competing interests
The authors disclose the following: Drs. Edith Vécsei, Stephanie
Steinwendner, Hubert Kogler, Albina Innerhofer, Karin Hammer, Oskar A.
Haas, Gabriele Amann, Andreas Chott, Harald Vogelsang, Regine
Schoenlechner, and Wolfgang Huf have no financial interests to disclose.
Dr. Andreas Vécsei has served as a consultant and scientific advisor for
Dr. Schär GmbH/Srl, Burgstall, BZ, Italy.
The study was partially supported by Dr. Schär GmbH/Srl, Burgstall, BZ, Italy,
and the St. Anna Fund, Vienna, Austria. Antibody kits were supplied free of
charge by Inova Diagnostics, Inc., Werfen Group. The study sponsors were
not involved in the study design, in the collection, analysis, interpretation of
data and in writing of the report.
Authors’ contributions
EV, SS, HK and AV jointly wrote the first draft of the manuscript. Furthermore,
EV developed the study design, the concept and the statistical analysis plan,
participated in data collection, interpreted the data and did the statistical
analysis and revised the paper; SS developed the study design, the concept
and the statistical analysis plan, participated in data collection and entry into
the data base, analyzed and interpreted the data; HK cleaned and
interpreted the data and participated in statistical analysis and revised the
paper and the tables; AI was responsible for the data collection, entry in the
database and clinical care of the study patients, critically revised the
manuscript for important intellectual content; KH was performing the
endoscopies, participated in data collection, was responsible for the clinical
care of the study patients, revised the draft paper; OAH was responsible for
the serological tests, revised the draft paper; GA and AC reviewed the
pathological slides, participated in data collection and revised the draft
paper; HV was responsible for the results of the intestinal permeability test
and critically revised the manuscript for important intellectual content; RS
participated in data collection and revised the paper; WH did the statistical
analysis, drafted the figures and critically revised the manuscript for
important intellectual content; AV developed the study design, the concept
and the statistical analysis plan, obtained the funding, monitored data
collection, interpreted the data and did the statistical analysis, drafted and
revised the paper and supervised the study. All authors read and approved
the final manuscript.
Author details
1Department of Pediatrics, Pediatric Gastroenterology, St. Anna Children's
Hospital, Medical University Vienna, Kinderspitalgasse 6, 1090 Vienna, Austria.
2Clinical Department of Pathology, Medical University Vienna, Vienna, Austria.
3Institute of Pathology and Microbiology, Wilhelminenspital, Vienna, Austria.
4Department of Internal Medicine III, Division for Gastroenterology and
Hepatology, Medical University of Vienna, Vienna, Austria. 5Department of
Food Science and Technology, Institute of Food Technology, University of
Natural Resources and Life Sciences, Vienna, Austria. 6Center for Medical
Physics and Biomedical Engineering, Medical University of Vienna, Vienna,
Austria.
Received: 30 January 2014 Accepted: 3 February 2014
Published: 13 February 2014
References
1. Oberhuber G, Granditsch G, Vogelsang H: The histopathology of coeliac
disease: time for a standardized report scheme for pathologists.
Eur J Gastroenterol Hepatol 1999, 11(10):1185–1194.
2. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA: Mucosal
recovery and mortality in adults with celiac disease after treatment with
a gluten-free diet. Am J Gastroenterol 2010, 105(6):1412–1420.
3. Kaukinen K, Peraaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P,
Karvonen AL, Laasanen T, Sievanen H, Maki M, et al: Persistent small bowel
mucosal villous atrophy without symptoms in coeliac disease.
Aliment Pharmacol Ther 2007, 25(10):1237–1245.
4. Lebwohl B, Granath F, Ekbom A, Smedby KE, Murray JA, Neugut AI, Green
PH, Ludvigsson JF: Mucosal healing and risk for lymphoproliferative
malignancy in celiac disease: a population-based cohort study.
Ann Intern Med 2013, 159(3):169–175.
5. Bai JC, Fried M, Corazza GR, Schuppan D, Farthing M, Catassi C, Greco L,
Cohen H, Ciacci C, Eliakim R, et al: World gastroenterology organisation
Vécsei et al. BMC Gastroenterology 2014, 14:28 Page 8 of 9
http://www.biomedcentral.com/1471-230X/14/28
global guidelines on celiac disease. J Clin Gastroenterol 2013,
47(2):121–126.
6. Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R,
Troncone R, Giersiepen K, Branski D, Catassi C, et al: European society for
pediatric gastroenterology, hepatology, and nutrition guidelines for the
diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012,
54(1):136–160.
7. Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg
EJ, Horvath K, Murray JA, Pivor M, et al: Guideline for the diagnosis and
treatment of celiac disease in children: recommendations of the North
American Society for Pediatric Gastroenterology, Hepatology and
Nutrition. J Pediatr Gastroenterol Nutr 2005, 40(1):1–19.
8. Dickey W, Hughes DF, McMillan SA: Disappearance of endomysial
antibodies in treated celiac disease does not indicate histological
recovery. Am J Gastroenterol 2000, 95(3):712–714.
9. Sategna-Guidetti C, Pulitano R, Grosso S, Ferfoglia G: Serum IgA
antiendomysium antibody titers as a marker of intestinal involvement
and diet compliance in adult celiac sprue. J Clin Gastroenterol 1993,
17(2):123–127.
10. Vecsei AK, Graf UB, Vogelsang H: Follow-up of adult celiac patients: which
noninvasive test reflects mucosal status most reliably?1. Endoscopy 2009,
41(2):123–128.
11. Hopper AD, Hadjivassiliou M, Hurlstone DP, Lobo AJ, McAlindon ME, Egner
W, Wild G, Sanders DS: What is the role of serologic testing in celiac
disease? A prospective, biopsy-confirmed study with economic analysis.
Clin Gastroenterol Hepatol 2008, 6(3):314–320.
12. Veress B, Franzen L, Bodin L, Borch K: Duodenal intraepithelial
lymphocyte-count revisited. Scand J Gastroenterol 2004, 39(2):138–144.
13. Conley ME, Notarangelo LD, Etzioni A: Diagnostic criteria for primary
immunodeficiencies. Representing PAGID (Pan-American Group for
Immunodeficiency) and ESID (European Society for Immunodeficiencies).
Clin Immunol 1999, 93(3):190–197.
14. Swets JA: Measuring the accuracy of diagnostic systems. Science 1988,
240(4857):1285–1293.
15. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under
two or more correlated receiver operating characteristic curves:
a nonparametric approach. Biometrics 1988, 44(3):837–845.
16. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver
operating characteristic (ROC) curve. Radiology 1982, 143(1):29–36.
17. Jaeschke R, Guyatt GH, Sackett DL: Users' guides to the medical literature.
III. How to use an article about a diagnostic test. B. What are the results
and will they help me in caring for my patients? The Evidence-Based
Medicine Working Group. JAMA 1994, 271(9):703–707.
18. R Core Team: R: A Language and Environment for Statistical Computing.
Vienna, Austria: R Foundation for Statistical Computing; 2013.
http://www.R-project.org/
19. Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S,
Korponay-Szabo IR: Accuracy of diagnostic antibody tests for coeliac
disease in children: summary of an evidence report. J Pediatr Gastroenterol
Nutr 2012, 54(2):229–241.
20. Koskinen O, Collin P, Korponay-Szabo I, Salmi T, Iltanen S, Haimila K, Partanen J,
Maki M, Kaukinen K: Gluten-dependent small bowel mucosal transglutaminase
2-specific IgA deposits in overt and mild enteropathy coeliac disease. J Pediatr
Gastroenterol Nutr 2008, 47(4):436–442.
21. Kurppa K, Rasanen T, Collin P, Iltanen S, Huhtala H, Ashorn M, Saavalainen P,
Haimila K, Partanen J, Maki M, et al: Endomysial antibodies predict celiac
disease irrespective of the titers or clinical presentation. World J
Gastroenterol 2012, 18(20):2511–2516.
22. Wahab PJ, Meijer JW, Mulder CJ: Histologic follow-up of people with celiac
disease on a gluten-free diet: slow and incomplete recovery. Am J Clin
Pathol 2002, 118(3):459–463.
23. Hogberg L, Grodzinsky E, Stenhammar L: Better dietary compliance in
patients with coeliac disease diagnosed in early childhood. Scand J
Gastroenterol 2003, 38(7):751–754.
24. Selby WS, Painter D, Collins A, Faulkner-Hogg KB, Loblay RH: Persistent
mucosal abnormalities in coeliac disease are not related to the ingestion
of trace amounts of gluten. Scand J Gastroenterol 1999, 34(9):909–914.
25. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G: Long-term follow-up of celiac
adults on gluten-free diet: prevalence and correlates of intestinal
damage. Digestion 2002, 66(3):178–185.
26. Lebwohl B, Granath F, Ekbom A, Montgomery SM, Murray JA, Rubio-Tapia A,
Green PH, Ludvigsson JF: Mucosal healing and mortality in coeliac
disease. Aliment Pharmacol Ther 2013, 37(3):332–339.
27. Sharkey LM, Corbett G, Currie E, Lee J, Sweeney N, Woodward JM:
Optimising delivery of care in coeliac disease - comparison of the
benefits of repeat biopsy and serological follow-up. Aliment Pharmacol Ther
2013, 38(10):1278–1291.
28. Basso D, Guariso G, Fogar P, Meneghel A, Zambon CF, Navaglia F, Greco E,
Schiavon S, Rugge M, Plebani M: Antibodies against synthetic deamidated
gliadin peptides for celiac disease diagnosis and follow-up in children.
Clin Chem 2009, 55(1):150–157.
29. Bardella MT, Velio P, Cesana BM, Prampolini L, Casella G, Di Bella C, Lanzini
A, Gambarotti M, Bassotti G, Villanacci V: Coeliac disease: a histological
follow-up study. Histopathology 2007, 50(4):465–471.
30. Ravelli A, Bolognini S, Gambarotti M, Villanacci V: Variability of histologic
lesions in relation to biopsy site in gluten-sensitive enteropathy.
Am J Gastroenterol 2005, 100(1):177–185.
31. Arguelles-Grande C, Tennyson CA, Lewis SK, Green PH, Bhagat G: Variability
in small bowel histopathology reporting between different pathology
practice settings: impact on the diagnosis of coeliac disease. J Clin Pathol
2012, 65(3):242–247.
doi:10.1186/1471-230X-14-28
Cite this article as: Vécsei et al.: Follow-up of pediatric celiac disease:
value of antibodies in predicting mucosal healing, a prospective cohort
study. BMC Gastroenterology 2014 14:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vécsei et al. BMC Gastroenterology 2014, 14:28 Page 9 of 9
http://www.biomedcentral.com/1471-230X/14/28
